- Home
- JHI vs STTK Comparison
JHI vs STTK Comparison
Compare JHI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- STTK
- Stock Information
- Founded
- JHI 1971
- STTK 2016
- Country
- JHI United States
- STTK United States
- Employees
- JHI N/A
- STTK N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- STTK Health Care
- Exchange
- JHI Nasdaq
- STTK Nasdaq
- Market Cap
- JHI 119.9M
- STTK 119.0M
- IPO Year
- JHI N/A
- STTK 2020
- Fundamental
- Price
- JHI $13.66
- STTK $1.95
- Analyst Decision
- JHI
- STTK Hold
- Analyst Count
- JHI 0
- STTK 5
- Target Price
- JHI N/A
- STTK $3.00
- AVG Volume (30 Days)
- JHI 29.5K
- STTK 115.8K
- Earning Date
- JHI 01-01-0001
- STTK 11-06-2025
- Dividend Yield
- JHI 6.80%
- STTK N/A
- EPS Growth
- JHI N/A
- STTK N/A
- EPS
- JHI 1.05
- STTK N/A
- Revenue
- JHI N/A
- STTK $1,000,000.00
- Revenue This Year
- JHI N/A
- STTK N/A
- Revenue Next Year
- JHI N/A
- STTK N/A
- P/E Ratio
- JHI $12.47
- STTK N/A
- Revenue Growth
- JHI N/A
- STTK N/A
- 52 Week Low
- JHI $11.63
- STTK $0.69
- 52 Week High
- JHI $13.40
- STTK $2.71
- Technical
- Relative Strength Index (RSI)
- JHI 33.06
- STTK 46.73
- Support Level
- JHI $13.57
- STTK $1.72
- Resistance Level
- JHI $13.88
- STTK $2.07
- Average True Range (ATR)
- JHI 0.12
- STTK 0.17
- MACD
- JHI -0.01
- STTK -0.00
- Stochastic Oscillator
- JHI 2.47
- STTK 47.89
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.